MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15197596

Медицинская библиотека · Journal of clinical medicine · 2026

Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.

Wallington Michael, Chen Yong, Jie Fei, Patterson Monica, Repetny Karen, Fanale Michelle, Purcell Simon, Ambrose Jacob, Zettler Christina M, Belli Andrew J, Fernandes Laura L, Wang Ching-Kun

СтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with a defined, first-line (1L) standard of care (SOC). Several novel agents have been approved for the treatment of relapsed/refractory (R/R) disease in recent years, leading to a heterogeneous treatment landscape in later lines of therapy (LOTs). Our study aimed to characterize real-world treatment patterns for patients who received third-line or later (3L+) therapy using a multiple index date qualification methodology to enable a comparison to clinical trials.

Methods

This observational, retrospective study identified eligible patients in the COTA (now Verana Health) electronic health record-based, DLBCL dataset. Patients were assessed for eligibility at the initiation of each 3L+ LOT. The results were summarized overall and by qualification methodology, and the Kaplan-Meier method was used to evaluate real-world overall survival (rwOS).

Results

Among 476 unique patients, 716 index-LOTs were identified, and 3L+ index therapies were variable. The Eastern Cooperative Oncology Group (ECOG) score was 0-2 for 57% of qualifying-LOTs and missing/unknown (M/U) for 43%. The median rwOS among all-qualifying, first-qualifying, and last-qualifying index-LOTs was 8.0 (95% CI: 6.9, 10.6), 11.4 (95% CI: 9.7, 13.6), and 6.3 months (95% CI: 5.3, 8.0), respectively. Patients with M/U ECOG did not experience worse outcomes compared to those with ECOG 0-2.

Conclusions

The outcomes in our study are similar to those from comparator arms of contemporary clinical trials, demonstrating a continued unmet need for effective, SOC therapy for patients with 3L+ DLBCL. Additionally, the variable outcomes based on qualifying index-LOTs underscores the criticality of appropriate patient identification and comparison for clinical trials.

Для цитирования: Wallington Michael, Chen Yong, Jie Fei, Patterson Monica, Repetny Karen, Fanale Michelle, Purcell Simon, Ambrose Jacob, Zettler Christina M, Belli Andrew J, Fernandes Laura L, Wang Ching-Kun. Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15197596.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.